<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01895491</url>
  </required_header>
  <id_info>
    <org_study_id>VM206RY-VM01</org_study_id>
    <nct_id>NCT01895491</nct_id>
  </id_info>
  <brief_title>Safety Study of VM206RY in Subjects With Expression of HER2 in Breast Cancer</brief_title>
  <acronym>VM206RY</acronym>
  <official_title>An Open-Label, Uncontrolled, Single Center, Phase I Trial to Assess the Safety of VM206RY in Subjects With Expression of Her2 in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reyon Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reyon Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the safety of VM206RY in subjects with&#xD;
      expression of HER2 in breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events (including serious adverse events and adverse events lead to treatment discontinuation) will be described according to severity and to their relationship with the study drug and injection procedure.</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Up to 8 weeks</time_frame>
    <description>DLT was defined as adverse events higher than grade 3 based on NCI CTCAE version 4.0 with respect to their relationship with the study drug and injection procedure until 2 weeks after final injection. MTD was defined as the highest dose evaluated for which less than 1/3 of the participants experienced DLT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of HER2 specific antibody formation in plasma at pre and post injection using ELISA or FACS</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of HER2 specific CTL response on PBMC at pre and post injection using IFN-gamma ELISPOT</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tumor response based on the Response Evaluation Criteria in Solid Tumors (RECIST version 1.1)</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of HER2 level in plasma at pre and post injection using ELISA</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of GM-CSF level in plasma at pre and post injection using ELISA</measure>
    <time_frame>Up to be confirmed as negative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of VM206Ad in whole blood at pre and post injection using Q-PCR</measure>
    <time_frame>Up to be confirmed as negative</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>CohortⅠ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VM206DNA 6mg and VM206Ad 3*10^9VP injected into the brachial muscle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CohortⅡ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VM206DNA 12mg and VM206Ad 3*10^9VP injected into the brachial muscle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CohortⅢ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VM206DNA 24mg and VM206Ad 3*10^9VP injected into the brachial muscle</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VM206DNA</intervention_name>
    <arm_group_label>CohortⅠ</arm_group_label>
    <arm_group_label>CohortⅡ</arm_group_label>
    <arm_group_label>CohortⅢ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VM206Ad</intervention_name>
    <arm_group_label>CohortⅠ</arm_group_label>
    <arm_group_label>CohortⅡ</arm_group_label>
    <arm_group_label>CohortⅢ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women, 20 years of age&#xD;
&#xD;
          -  Stage 3 or 4 breast cancer&#xD;
&#xD;
          -  Unresectable breast cancer with Expression of Her2 and one of the following criteria&#xD;
             including&#xD;
&#xD;
               -  Prior use of Her2-targeted therapies(Herceptin, Tykerb, taxane and capecitabine)&#xD;
                  but it was not responding, with Immunohistochemistry (IHC) 3+, or IHC 2+ and&#xD;
                  FISH+, or SISH+&#xD;
&#xD;
               -  Patients received treatment that three times continuously Different&#xD;
                  chemotherapies but it was not responding, with Immunohistochemistry (IHC) 2+ and&#xD;
                  FISH- or SISH-, or Immunohistochemistry (IHC) 1+&#xD;
&#xD;
               -  Prior use of six chemotherapies(Anthracycline, Taxane, Gemcitabine, Capecitabine,&#xD;
                  Vinorelbine, Cyclophosphamide) but it was not responding, with&#xD;
                  Immunohistochemistry (IHC) 2+ and FISH or SISH-, or Immunohistochemistry (IHC) 1+&#xD;
&#xD;
          -  One or more measurable(or assessable) lesion of breast or metastatic site&#xD;
&#xD;
               -  Spiral CT: ≥ 10mm diameter&#xD;
&#xD;
               -  general measurement methods (CT, X-ray, MRI): ≥ 20mm diameter&#xD;
&#xD;
          -  Life expectancy 6 months&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior use of breast cancer vaccine&#xD;
&#xD;
          -  Active or history of cardiovascular diseases within the past 3 months: Active&#xD;
             uncontrolled cardiac disease, including cardiomyopathy, CHF(NYHA Class III~IV), and&#xD;
             unstable angina, family history of congenital long QT syndrome or QT/QTc interval&#xD;
             &gt;0.45 sec or torsade de points(TdP), and history of idiopathic ventricular tachycardia&#xD;
             or ventricular fibrillation, LVEF &lt; 50%&#xD;
&#xD;
          -  Patients with coronary artery disease (myocardial infarction, angina, etc.) or a&#xD;
             history of coronary artery disease&#xD;
&#xD;
          -  Patients who is required hospitalization by severe fever or required antibiotic&#xD;
             treatment by serious infection&#xD;
&#xD;
          -  Patients who is confirmed as CNS metastases. (Only, patient with stable brain&#xD;
             metastases is permit. Among the patients who have not any symptom, do not see the&#xD;
             progression before registered the last 2 month)&#xD;
&#xD;
          -  History of prior malignancies other than breast cancer within the past 5 years&#xD;
&#xD;
          -  Patients with an existing condition or a history of autoimmune disease or&#xD;
             immunodeficiency disease&#xD;
&#xD;
          -  ECOG score ≥ 3&#xD;
&#xD;
          -  Patients with severe dysfunction in major organs&#xD;
&#xD;
               -  Blood: WBC &lt; 3,000/㎕; Platelet &lt; 100,000/㎕; Hematocrit &lt; 30&#xD;
&#xD;
               -  Liver: Total bilirubin ≥ 1.5 x ULN; ALT/AST ≥ 2.5 x ULN&#xD;
&#xD;
               -  Kidney: Creatinine ≥ 1.5 x ULN&#xD;
&#xD;
          -  Abnormal values of anti-nuclear Ab, anti-double-stranded DNA and C3, as judged by the&#xD;
             investigator&#xD;
&#xD;
          -  History of surgical procedure, chemotherapy, Herceptin treatment, corticosteroid&#xD;
             therapy, immunosuppressant therapy or radiotherapy within the past 4 weeks&#xD;
&#xD;
          -  HIV Ag/Ab, HBs Ag, HCV Ab or HTLV-1 Ab positive&#xD;
&#xD;
          -  Psychotropic drug misuse/abuse or alcoholism&#xD;
&#xD;
          -  Prior use of vaccine within the past 4 weeks&#xD;
&#xD;
          -  Cumulative dose of prior doxorubicin &gt; 360 ㎎/㎡ or epirubicin &gt; 720 ㎎/㎡&#xD;
&#xD;
          -  Women who is pregnant or breastfeeding and don't agree to use a contraceptive during&#xD;
             the study period.&#xD;
&#xD;
          -  Patients who have participated in clinical trials enrolled in this clinical trial&#xD;
             within 4 weeks before. (Only patient, who has taken survey and DNA test without&#xD;
             drug-treatment, has permit.)&#xD;
&#xD;
          -  Patients who are ineligible to participate in this study, as judged by the&#xD;
             investigator.&#xD;
&#xD;
          -  Patients who prohibit administering GM-CSF and prior use of GM-CSF within the past 4&#xD;
             weeks.&#xD;
&#xD;
          -  Patients who expect hypersensitivity to investigational product (VM206RY) or any&#xD;
             component of product.&#xD;
&#xD;
          -  Due to malignancy neoplasm, patients who require supplementary oxygen or has severe&#xD;
             dyspnea at rest&#xD;
&#xD;
          -  Patients with hypertension [inadequately controlled hypertension (systolic &gt; 180 mm Hg&#xD;
             or diastolic &gt; 100 mm Hg)] or a history of hypertension&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>June 12, 2013</study_first_submitted>
  <study_first_submitted_qc>July 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2013</study_first_posted>
  <last_update_submitted>January 20, 2015</last_update_submitted>
  <last_update_submitted_qc>January 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

